XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Collaborations, contracts and licensing agreements (Tables)
 6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of deferred collaborations and contracts revenue The following table outlines the transaction price and the changes to the related asset and liability balances during the six months ended June 30, 2022:
Six Months Ended June 30, 2022
Transaction PriceCumulative Collaboration Revenue RecognizedDeferred License Revenue
(in thousands)
Combined performance obligation$49,270 $20,655 $28,615 
Less contract asset(800)
Total deferred license revenue27,815 
Less current portion of deferred license revenue16,973 
Non-current deferred license revenue$10,842 
Summary of collaborations
Revenues are summarized in the following table:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
(in thousands)(in thousands)
Revenue from collaborations and licenses
Acuitas Therapeutics, Inc.$1,550 $1,163 $3,084 $2,258 
Qilu Pharmaceutical Co., Ltd.11,024 — 20,655 — 
Other milestone and royalty payments(18)22 35 81 
Non-cash royalty revenue
Alnylam Pharmaceuticals, Inc.1,685 1,144 3,048 2,103 
Total revenue$14,241 $2,329 $26,822 4,442